That’s all fine, except those are all issues with our insurance model as opposed to the pharmaceutical industry. Why not fix the actual problem by addressing th

That’s all fine, except those are all issues with our insurance model as opposed to the pharmaceutical industry. Why not fix the actual problem by addressing the labyrinth of middlemen in between the person consuming the medication, the doctor prescribing it, and the company producing it? That seems like a far better idea than making drug development non-profit, reducing the incentives for innovation and new discovery.